A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors

Patients with pancreatic neuroendocrine tumors (PNETs) commonly develop advanced disease and require systemic therapy. However, treatment options remain limited, in part because experimental models that reliably emulate PNET disease are lacking. We therefore developed a patient-derived xenograft mod...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Chamberlain, Chester E., German, Michael S., Yang, Katherine, Wang, Jason, VanBrocklin, Henry, Regan, Melanie, Shokat, Kevan M., Ducker, Gregory S., Kim, Grace E., Hann, Byron, Donner, David B., Warren, Robert S., Venook, Alan P., Bergsland, Emily K., Lee, Danny, Wang, Yucheng, Nakakura, Eric K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279485/
https://ncbi.nlm.nih.gov/pubmed/30254185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados